Keeping Connectivity Within Reach, OPPO Launches Its First Smartwatch With Thales’ eSIM Solutions
7.9.2020 09:00:00 EEST | Business Wire | Press release
OPPO, the world's leading smart device manufacturer, has selected Thales’ set of eSIM products and services for its OPPO Watch, the brand’s first smartwatch series with built-in cellular connectivity. The launch of the OPPO Watch marks a strategic step into the field of IoT for the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200906005025/en/
OPPO Watch © OPPO
One of the most compelling features of the OPPO Watch is the eSIM-based cellular connectivity. Thales’ eSIM allows OPPO Watch users to enjoy a smoothly digital experience by activating a mobile subscription remotely and always stay connected without having to tether it to a mobile phone. Users can make voice calls or send messages at any time directly through the smartwatch, providing seamless connectivity during workouts or other situations where carrying a mobile phone is inconvenient. This smooth experience leverages Thales eSIM solutions to offer a full range of subscription services during the life cycle of the device.
By eliminating the need for an additional SIM card slot, Thales’ eSIM makes sleek mobile-connected smartwatches possible. Indeed it enables a thinner and lighter smartwatch design while freeing up more space for extra features such as up to 50 meter water resistance. It thereby helps OPPO fulfil its mission of elevating life through technological artistry.
The Thales embedded SIM has been qualified by all three China’s mobile operators allowing OPPO smartwatch users to select their mobile subscription from any of these operators.
“As OPPO's first foray into the wearable electronics market, the OPPO Watch marks a strategic step into the field of AIoT (Artificial IoT) for the company. Thanks to Thales' eSIM solutions that bring smartphone-level convenience to smartwatches, users can stay connected in a smarter and more efficient way without restrictions. We are looking forward to working with Thales again, given their leadership in eSIM and the success of our current partnership.”
Liu Bo, President of OPPO China
“The wearable segment is the second largest market for eSIM-compliant consumer electronics after smartphones. ABI Research forecasts that a total of 315 million cellular enabled wearables will have shipped by 2025. Smartwatch makers, in particular, are increasingly on-boarding eSIM connectivity in their flat-design devices to address new smartwatch-only use cases such as kids safety, sports and health monitoring...”
David McQueen, Director, Connected Consumer Devices, ABI Research
Research
“Thales is honoured to provide a full suite of eSIM solutions for OPPO Watch. AIoT is one of OPPO’s key focuses aiming to bring customers seamless experiences to their daily life, including sport and health. Thales is OPPO’s key eSIM solutions partner, empowering them with instant connectivity for their consumer devices. We are proud to accompany OPPO on this journey and fully support their ambitions of providing their users with the best innovations available.”
Jérôme Bendell, Vice President of Thales North Asia and CEO of Thales in China
Thales is the world's leader in eSIM connectivity management with more than 200 eSIM management platforms awarded by mobile operators, operator alliances, MVNOs, automotive makers, and OEMs across all continents.
Related resources:
What is an eSIM: 6 illustrated answers
infographic
4 ways to activate eSIM-capable consumer IoT devices
dossier
Best practices for optimising eSIM adoption
eBook
Innovative eSIM use cases such as prepaid offers for inbound travelers and family bundle
dossier
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations – connectivity, Big Data, artificial intelligence and cybersecurity – technologies that support businesses, organisations and governments in their decisive moments.
About Thales in China
Thales provides innovative solutions for the infrastructure that forms the backbone of China’s growth. The Group has been present in China for around 40 years and is the trusted partner for the Chinese aviation and urban rail transportation industries. In the meanwhile, from secure software to biometrics and encryption, Thales has successfully applied its advanced technology to mobile communication, banking, IoT and software monetization etc. Thales has 3 JVs and employs 2,300 people with offices located in 8 cities in China. Thales established R&D centers and Innovation Hubs in Beijing, Dalian and Hong Kong to provide innovative solutions for both China and international market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200906005025/en/
Contact information
PRESS
Head of Government Affairs & Communications
Thales in China
Tammy Qiu
+86 10 65875066
tammy.qiu@asia.thalesgroup.com
Thales, Media Relations
Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
